written by reader Oxford Club’s seminar on Biosimilar drugs

By radesrochers, May 29, 2015

Guys, I just listened to the Oxford Clubs ”seminar” on the impending surge in the use of Biosimilar drugs in the US. They want you to subscribe to a newsletter and will give you the five ”best” stocks to retire on if you pay the price. Does anyone have any idea what they are as well as any thoughts about how rewarding they may become?

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

4 Comments
Inline Feedbacks
View all comments
Shanghai
Shanghai
5 years ago

I do not know the right answer for your question, but I read a teaser from Paul Mampily’s research: “He’s also shared another company with a powerful medical database. It’s so valuable that Wal-Mart pays an estimated $6 million a year to allow its employees access. Other big companies are doing the same, including Kraft and CVS Health.” Does anyone have a clue that which company is it? I have not found anything about it. Thank you for your help in advance.

Add a Topic
976
Victor Harberson
5 years ago

I hate to go off subject but this company has been in business five years looking for cfo lithium is a projected to grow so much we can not handle it all the website is SMARTBATTARY.com take a look are customers include nasa fm us navy coastguard army looking for equity partner To come in already been contacted by shark tank but we need a full time cfo or ceo sorry again but if anybody could point us in right direction really be thankful lot of money to be made

Add a Topic
2096
SoGiAm
5 years ago

A couple biosimilar equities that our Irregular super-sleuth, Glenn mentioned are:
MNTA-Momenta Pharmaceuticals, Inc. is a biotechnology company operating in three product areas: Complex Generics, Biosimilars and Novel Drugs. The Company’s approach is built around a complex systems analysis platform that it uses to obtain a detailed understanding of complex chemical and biologic systems, design product candidates, analyze sets of biological data to evaluate the biological function of its products and develop manufacturing processes that enable its products to be reliably produced. The Company uses its complex systems analysis platform to define the detailed structures present in these complex drugs. To demonstrate that the biological function of the Company’s generic replicates that of the brand, the Company utilizes its complex systems analysis platform to evaluate and compare multiple orthogonal sets of biologic data from in-vitro, in-vivo and ex-vivo models.
and
PFNX-Pfenex Inc. is a clinical-stage biotechnology Company. The Company is engaged in the development of difficult to manufacture and high-value proteins, initially focused on biosimilar therapeutics. The Company’s core technology, Pfenex Expression Technology for recombinant protein expression, is able to rapidly develop and produce high quality therapeutics. The Company’s Pfenex Expression Technology combines a toolbox of expression components with a robotically enabled high-throughput parallel strain screening technology, delivering speed and success in identifying protein production strains expressing high titers of soluble, active protein. The Company’s lead product candidate is PF582, a biosimilar candidate. It is used for the treatment of retinal diseases. The Company’s other product candidate is PF530, is for the treatment of multiple sclerosis. The Company is developing Px563L, an anthrax vaccine candidate.
Thanks Glenn! Best2ALL-Benjamin

👍 11476
Jane
Jane
5 years ago

I am interested in investing in a stock that covers Pinpoint Surgery. Do any of you know what stock this is?

Add a Topic
5971
Add a Topic
6225
Add a Topic
5971

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info